These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 17355742

  • 1. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 2. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
    Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):501-15. PubMed ID: 19640359
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
    Beaudet A, Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, Lloyd A.
    J Med Econ; 2011 Aug; 14(3):357-66. PubMed ID: 21563878
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H.
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
    Deng J, Gu S, Shao H, Dong H, Zou D, Shi L.
    J Med Econ; 2015 Nov; 18(11):974-89. PubMed ID: 26134916
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
    Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, Dilla T.
    Endocrinol Nutr; 2011 Jun; 58(7):331-40. PubMed ID: 21719364
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T.
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.